Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Mandy Jackson
The total cost of Zolgensma is more than $2m – in line with estimates – or $425,000 annually for five years if payers choose an annuity-like payment plan. Novartis is also negotiating value-based reimbursement agreements for infants treated with the one-time infusion.
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
ElevateBio revealed the first company to hitch up with its newly established centralized cell and gene therapy development, manufacturing and commercial capabilities – AlloVir, formerly ViraCyte, which is developing T-cell therapies to treat viruses in immunocompromised patients.
Investors in Peloton, which has the only clinical-stage HIF-2α inhibitor, will get back 3.5 times the $304m in venture capital invested in the firm via the $1.1bn that Merck is paying up front. With all $1.15bn in additional milestone fees, the return could grow to 7.2x.
The company reported positive Phase II results and will move its potential fourth-to-market IL-23 inhibitor into Phase III in Crohn's disease later this year. Mirikizumab – in Phase III for psoriasis and ulcerative colitis – may be the second IL-23 drug for an IBD indication.
The start-up run by ex-Lumena leadership is testing REN001 for rare genetic mitochondrial diseases with two Phase Ib trials under way and plans to start a third later this year.